Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy.

Wüstemann T, Haberkorn U, Babich J, Mier W (2019) Targeting prostate cancer: Prostate-specific membrane antigen based diagnosis and therapy. Med Res Rev 39(1):40-69. doi: 10.1002/med.21508

Summary: Conjugation to the antibody was achieved by reacting the biotinylated humanized antibody to prostate-specific membrane antigen (PMSA) with Streptavidin-ZAP. Binding potency of the conjugate was comparable to that of the naked antibody and in vivo experiments proved potent for selective tumor growth inhibition in mice bearing LNCaP tumors.

Related Products: Streptavidin-ZAP (Cat. #IT-27)

See Also:

• Kuroda K et al. Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. Prostate 70(12):1286-1294, 2010.